Detalhe da pesquisa
1.
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
N Engl J Med
; 374(21): 2054-64, 2016 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27223147
2.
The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease.
Blood
; 123(26): 4037-44, 2014 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-24786773
3.
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.
Blood
; 122(11): 1954-62, 2013 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23926300
4.
Activated prothrombin complex concentrate (FEIBA® ) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry.
Br J Haematol
; 184(5): 853-855, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29528100
5.
Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.
Semin Thromb Hemost
; 37(5): 511-21, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22102194
6.
Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days: A case-control study.
J Thromb Haemost
; 19(9): 2171-2181, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34107158
7.
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.
J Clin Invest
; 125(10): 3766-81, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26426076